| | | |  | | | | By Adam Feuerstein NIAID Natural killer cells (NK cells) and a "matchmaker" called AFM13 elicited remissions in a trial of patients with advanced Hodgkin lymphoma. Read More | | By Matthew Herper AP/Business Wire A new study finds benefits to giving an immunotherapy made by Bristol-Myers Squibb to lung cancer patients before surgery. Read More | | By Angus Chen Angus Chen CAR T-therapy has had lackluster success against solid tumors. Boosting it with an mRNA vaccine appears to make it more effective. Read More | | Sponsor content by Olema Oncology Evolving the standard of care for advanced breast cancer Though there has been meaningful progress in treating breast cancer over the past two decades, limited treatment options exist for metastatic or advanced breast cancers, with the 5-year survival rate hovering around 28%. Dr. Sean P. Bohen, President and CEO of Olema Oncology, discusses the need to accelerate innovation, address limitations in current therapies, improve the patient experience, and advance the standard of care for women's cancers. Read more. | | By Angus Chen OncoNano Medicine Making pH-sensitive nanoparticles packed with cancer-fighting drugs could be a way to treat tumors with fewer side effects. Read More | | By Ed Silverman Charlie Neibergall/AP Part D beneficiaries who have low incomes and receive subsidies were nearly twice as likely to fill a prescription as those without subsidies. Read More | |
No comments